Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
China · Delayed Price · Currency is CNY 136.75
-1.50 (-1.08%)
At close: Feb 13, 2026
Beijing Hotgen Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 428.55 | 505.01 | 544.62 | 3,532 | 5,307 | 511.67 |
Other Revenue | 5.89 | 5.89 | 3.22 | 24.41 | 62.65 | 1.86 |
| 434.45 | 510.9 | 547.84 | 3,557 | 5,369 | 513.53 | |
Revenue Growth (YoY) | -17.57% | -6.74% | -84.60% | -33.76% | 945.54% | 144.06% |
Cost of Revenue | 212.79 | 257.18 | 211.72 | 1,766 | 2,254 | 189.95 |
Gross Profit | 221.65 | 253.72 | 336.11 | 1,790 | 3,116 | 323.59 |
Selling, General & Admin | 316.68 | 289.77 | 258.6 | 483.58 | 404.26 | 161.44 |
Research & Development | 103.59 | 113.31 | 132.88 | 191.14 | 131.92 | 47.61 |
Other Operating Expenses | 7.38 | 3.45 | 3.58 | 9.2 | 5.04 | 0.88 |
Operating Expenses | 430.38 | 407.9 | 381.66 | 695.26 | 541.92 | 211.13 |
Operating Income | -208.73 | -154.18 | -45.55 | 1,095 | 2,574 | 112.46 |
Interest Expense | -0.46 | -0.45 | -1.01 | -2.32 | -1.27 | -0.45 |
Interest & Investment Income | 58.96 | 32.85 | 39.59 | 34.52 | 34.26 | 8.42 |
Currency Exchange Gain (Loss) | -0.78 | -0.78 | 4.31 | 4.95 | -14.64 | 1.7 |
Other Non Operating Income (Expenses) | -1.93 | 0.24 | -1.27 | 3.31 | -4.82 | -0 |
EBT Excluding Unusual Items | -152.94 | -122.32 | -3.92 | 1,135 | 2,587 | 122.12 |
Gain (Loss) on Sale of Investments | -51.89 | -9.36 | -23.68 | 7.52 | 3.12 | - |
Gain (Loss) on Sale of Assets | -2.6 | -1.63 | -0.64 | -0.34 | -14.21 | -0.18 |
Asset Writedown | -60.59 | -60.85 | -41.79 | -70.06 | -8.51 | -0.14 |
Other Unusual Items | 5.85 | 6.29 | 85.02 | 2.63 | 14.22 | 5.62 |
Pretax Income | -262.16 | -187.87 | 14.99 | 1,075 | 2,582 | 127.42 |
Income Tax Expense | 1.58 | 8.06 | -1.73 | 150.1 | 379.44 | 16.13 |
Earnings From Continuing Operations | -263.74 | -195.94 | 16.71 | 925.12 | 2,202 | 111.3 |
Minority Interest in Earnings | 4.41 | 4.93 | 12.21 | 19.62 | -16.61 | 0.77 |
Net Income | -259.33 | -191 | 28.92 | 944.74 | 2,186 | 112.07 |
Net Income to Common | -259.33 | -191 | 28.92 | 944.74 | 2,186 | 112.07 |
Net Income Growth | - | - | -96.94% | -56.78% | 1850.41% | 230.80% |
Shares Outstanding (Basic) | 90 | 92 | 88 | 91 | 92 | 92 |
Shares Outstanding (Diluted) | 90 | 92 | 88 | 92 | 92 | 92 |
Shares Change (YoY) | -1.31% | 4.59% | -3.88% | -0.14% | -0.12% | 23.13% |
EPS (Basic) | -2.90 | -2.07 | 0.33 | 10.33 | 23.75 | 1.22 |
EPS (Diluted) | -2.90 | -2.07 | 0.33 | 10.28 | 23.75 | 1.22 |
EPS Growth | - | - | -96.81% | -56.72% | 1852.80% | 168.66% |
Free Cash Flow | -43.64 | -88.57 | -461.9 | 413.54 | 2,246 | -7.65 |
Free Cash Flow Per Share | -0.49 | -0.96 | -5.23 | 4.50 | 24.40 | -0.08 |
Dividend Per Share | - | - | 0.200 | - | 3.378 | 1.014 |
Dividend Growth | - | - | - | - | 233.34% | 400.00% |
Gross Margin | 51.02% | 49.66% | 61.35% | 50.34% | 58.03% | 63.01% |
Operating Margin | -48.05% | -30.18% | -8.31% | 30.79% | 47.93% | 21.90% |
Profit Margin | -59.69% | -37.39% | 5.28% | 26.56% | 40.71% | 21.82% |
Free Cash Flow Margin | -10.04% | -17.34% | -84.31% | 11.63% | 41.82% | -1.49% |
EBITDA | -107.05 | -69.84 | 15.66 | 1,184 | 2,631 | 141.61 |
EBITDA Margin | -24.64% | -13.67% | 2.86% | 33.30% | 49.00% | 27.57% |
D&A For EBITDA | 101.68 | 84.33 | 61.2 | 89.39 | 57.5 | 29.15 |
EBIT | -208.73 | -154.18 | -45.55 | 1,095 | 2,574 | 112.46 |
EBIT Margin | -48.05% | -30.18% | -8.31% | 30.79% | 47.93% | 21.90% |
Effective Tax Rate | - | - | - | 13.96% | 14.70% | 12.66% |
Revenue as Reported | 434.45 | 510.9 | 547.84 | 3,557 | 5,369 | 513.53 |
Advertising Expenses | - | 15.59 | 13.38 | 55.08 | 68.41 | 7.17 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.